#USA #Menlo Park #Obesity Treatment #Phenomix Sciences #MyPhenome

Phenomix Sciences Launches MyPhenome Test

Phenomix Sciences has made a significant advancement in obesity management by directly offering the MyPhenome® genetic obesity test to patients. This innovative test goes beyond standard GLP-1 treatment responses, empowering individuals to take control of their weight loss journey by identifying tailored treatment options that align with their unique genetic makeup.

A Revolutionary Approach to Obesity Treatment

With over 30 million Americans currently using GLP-1 medications, many are experiencing limited weight loss results. This inconsistency poses a challenge as patients often resort to alternative treatments, sometimes at a higher cost, without understanding why those options may be more suitable for them. MyPhenome aims to bridge this gap by providing insights into the biological factors influencing obesity and how different treatments might align with those factors.

The MyPhenome test is the first and only precision obesity test available to patients directly, allowing them to understand the genetic underpinnings of their obesity. This initiative underscores Phenomix's commitment to delivering personalized healthcare solutions, enabling more effective treatment pathways.

How MyPhenome Works

The testing process is straightforward — patients can visit MyPhenome's website, complete a short questionnaire, and order a test kit that is shipped to their home. After collecting a simple cheek swab sample, patients return it via prepaid mail. Within two to three weeks, they receive a personalized report through a secure portal that reveals which genetic factors may be contributing to their weight gain.

These factors could range from the 'Hungry Gut', which refers to a quick return of hunger after meals, to 'Hungry Brain', which involves needing larger portions to feel satiated. Additionally, Emotional Hunger denotes eating driven by cravings or stress. The report helps healthcare providers to formulate customized treatment plans that may include lifestyle changes, dietary adjustments, or weight loss medications — including lower-cost options that might be more effective for the individual's specific biological scenario.

Mark Bagnall, CEO of Phenomix Sciences, stated, "GLP-1s have transformed obesity treatment, but they're not the only option, nor are they suitable for every patient. We believe that patients have the right to understand all available treatments and select ones that best fit their biology. That's what MyPhenome was created for."

Addressing the Patient Experience

Many patients express frustration when their weight loss efforts do not yield expected results, leading to feelings of hopelessness regarding their health journeys. As Liv Williamsen, COO of Phenomix, notes, "Patients often feel like they’re doing everything right, yet they struggle with weight loss. Learning that another medication could potentially suit their biology better is vital for them to regain hope and make informed decisions about their treatment."

The clinical data supports the benefits of phenotype-guided obesity treatments which have shown to be twice as effective as traditional methods. MyPhenome has proven successful by aligning patients with effective therapies based on an extensive foundational study of around 1,000 participants, employing an advanced AI platform analyzing over 20,000 genes. This groundbreaking approach harnesses decades of research conducted at the Mayo Clinic to not only enhance individual patient care but also inform future obesity treatment research and development.

Conclusion

The MyPhenome genetic obesity test is currently available, equipping patients with the insights needed to understand the factors influencing their weight gain effectively. For those interested in obtaining this test, visit myphenometest.com today. As Phenomix Sciences continues to lead the way in personalized weight management solutions, it opens doors for patients to gain autonomy over their health and pursue more effective obesity treatments in line with their biological profiles.